Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS

Diabetes, Metabolic Syndrome and Obesity

Volumn 4, Issue , 2011, Pages 78-88

  Holko, Przemyslaw ^a   Kawalec, Pawal ^a  

^a Centrum HTA w Krakowie   (Poland)

Author keywords

Blood glucose self monitoring; Costs and cost analysis; Diabetes complications; Diabetes mellitus; Health care costs

Indexed keywords

ADULT; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FUNDING; GLYCEMIC CONTROL; HUMAN; INTERMETHOD COMPARISON; QUALITY ADJUSTED LIFE YEAR; SELF MONITORING; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 79953115757     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S9395     Document Type: Article

References (23)

1. Vinik AI, Vinik E. Prevention of the complications of diabetes. Am J Manag Care. 2003;9(3 Suppl):S63-S80.
2. International Diabetes Federation. Diabetes Atlas. Diabetes [homepage on the Internet]. Available from: http://www.diabetesatlas.org/content/diabetes. Accessed November 23, 2010.
3. Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab. 2008;34(6):612-616.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
5. Kruger DF, Martin CL, Sadler CE. New insights into glucose regulation. Diabetes Educ. 2006;32(2):221-228.
6. Steffes MW. Glycemic control and the initiation and progression of the complications of diabetes mellitus. Kidney Int Suppl. 1997;63: S36-S39.
7. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care. 2001; 24(1):51-55.
8. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285(2):182-189.
9. Raine CH, Schrock LE, Edelman SV, et al. Significant insulin dose errors may occur if blood glucose results are obtained from miscoded meters. J Diabetes Sci Technol. 2007;1(2):205-210.
10. Kristensen GB, Nerhus K, Thue G, Sandberg S. Standardized evaluation of instruments for self-monitoring of blood glucose by patients and a technologist. Clin Chem. 2004;50(6):1068-1071.
11. Frank J, Rivera L, Wallace JF, Parkes JL. Performance and Ease of Use of the CONTOURTM™ TS Blood Glucose Monitoring System: Capillary, Venous and Alternative Site Testing (AST) Blood. Tarrytown, NY: Bayer Health Care Diabetes Care; 2007.
12. Tufts Medical Center, Institute for Clinical Research and Health Policy Studies. The Cost Effectiveness Analysis Registry Database, Center for the Evaluation of Value and Risk in Health (CEVR) [homepage on the Internet]. Available from: https://research.tufts-nemc.org/cear/. Accessed December 3, 2008.
13. Ministerstwo Zdrowia. Internet portal of the Ministry of Health [homepage on the Internet]. Available from: http://www.mz.gov.pl/. Accessed November 11, 2008.
14. Medycyna Praktyczna Portal [homepage on the Internet]. Available from: http://www.mp.pl. Accessed November 11, 2008.
15. Health Technology Assessment Agency website [homepage on the Internet]. Available from: http://www.aotm.gov.pl/. Accessed November 11, 2008.
16. Central Statistical Office of Poland. National Census of People and Dwellings 2011 [homepage on the Internet]. Available from: http://www.stat.gov.pl./gus/index_ENG_HTML.htm. Accessed November 23,
17. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care. 2004;27(7):1761-1773.
18. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007;335(7611):132.
19. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20 Suppl 1: S5-S26.
20. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-412.
21. Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract. 1998; 42(2):77-83.
22. Kumala-Szczeklik Z, Tatón J. Wplyw cukrzycy na wsakaŸniki chorobowooeci I oemiertelnooecu w powodu ostrego zawalu serca. Medycyna Metaboliczna. 1999;92:169-173.
23. Wiener K, Roberts NB. Age does not influence levels of HbA1c in normal subject. QJM. 1999;92(3):169-173.